ART Advanced Research Technologies Inc.
TSX : ARA

ART Advanced Research Technologies Inc.

September 09, 2008 11:40 ET

ART Advanced Research Technologies Molecular Imaging Platform Showcased at the World Molecular Imaging Congress in France

MONTREAL, CANADA--(Marketwire - Sept. 9, 2008) - ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announced today that current research relating to its molecular imaging products will be presented at the World Molecular Imaging Congress (WMIC), being held at the Nice Acropolis Convention Centre in Nice, France, from September 10 to 13, 2008. ART is also featuring the Optix® and Fenestra® preclinical product offering as an exhibitor at the event (booth #211), in the Exhibit Hall of the Nice Acropolis Convention Center.

Prior to the start of the meeting - on Wednesday, September 10 - ART will hold a ART User Forum, where Optix users and research scientists will present their work, and provide an opportunity for potential clients to learn about new developments and applications available for the Optix system, as well as the capability for translational research using the SoftScan® breast imaging device. Both products are based on the proprietary time domain technology developed by ART.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is used by industry and academic leaders worldwide. The SoftScan® optical medical imaging device is designed to improve the diagnosis and treatment of breast cancer. Finally, the Fenestra® line of molecular imaging contrast products provides image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART is commercializing some of these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca.

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in ART's most recent Annual Information Form and the financial statements for the year ended December 31, 2007, available on SEDAR (www.sedar.com).

Contact Information

  • ART Advanced Research Technologies Inc.
    Jacques Bedard
    Chief Financial Officer
    514-832-0777
    jbedard@art.ca
    or
    ART Advanced Research Technologies Inc.
    Dino DiCamillo, Vice President, Global Sales and
    Marketing, Preclinical Research
    514-832-0777
    ddicamil@art.ca
    www.art.ca